Dr. Harvey Kaufman, Senior Medical Director and head of the Health Trends™ Research Program at Quest Diagnostics discusses a recent study of the skyrocketing increase in the use of heroin and fentanyl as well as dangerous drug combining during the onset of the pandemic. He talks about how the decrease in urine drug testing at the onset of pandemic has contributed to the disturbing increase in addiction and fatal overdoses and what could be contributing to these trends, including the impact that the prolonged delay in elective care has had on the substance use disorders and recovery community.
Dr. Harvey Kaufman is a Senior Medical Director, Medical Informatics at Quest Diagnostics. In that capacity Harvey leads the Information Ventures health informatics analyst team. He also leads Quest’s Health Trends efforts. Harvey joined the company in 1992 as Medical Director in Cambridge, Massachusetts. He was the first Chief Laboratory Officer for Quest Diagnostics, the first Six Sigma Quality leader and the first medical director of Hospital Services, Business Development, International and Clinical Trials, as well as Health and Wellness. Harvey has been involved with Quest Diagnostics Health Trends™ since its inception in 2005 and has provided medical support for many of our informatics activities. He earned a medical degree from the Boston University School of Medicine, a master’s degree in molecular biology from MIT and an MBA in marketing from NYU’s Stern School of Business.